• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Biphasic insulin aspart in the treatment of type 2 diabetes mellitus.
【24h】

Biphasic insulin aspart in the treatment of type 2 diabetes mellitus.

机译：天冬胰岛素双相治疗2型糖尿病。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Initiating and implementing insulin treatment in type 2 diabetic subjects is a major challenge in diabetes clinical practice. Although simple regimens, such as the combination of a once-daily basal insulin + oral agents, are widely used, they often are not able to achieve an adequate glycemic control, especially in the postprandial period. Biphasic insulin analogues are a valid tool to start and to improve insulin treatment in type 2 diabetes. Biphasic insulin aspart (BIAsp) is available in three different mixtures (30, 50 and 70% of rapid-acting insulin, respectively), which allows insulin treatment to be individualized. OBJECTIVE/METHODS: To review recent published papers concerning pharmacological properties and clinical use of BIAsp in type 2 diabetes. RESULTS/CONCLUSION: BIAsp seems to have some advantages over biphasic human insulins, especially for its practical pre- or post-meal administration and lesser hypoglycemic risk. Against basal insulins once daily, BIAsp twice daily seems to perform better in achieving the glucose targets and, even when compared with the more complex basal-bolus regimens, a BIAsp-based treatment using the different available mixtures is at least non-inferior. Side effects are no more frequent than with other insulins; more hypoglycemic episodes of low severity have been sometimes reported, but only in comparison with basal insulin.
机译：背景：在2型糖尿病患者中开始和实施胰岛素治疗是糖尿病临床实践中的主要挑战。尽管简单的方法，例如每日一次基础胰岛素+口服药物的组合，已被广泛使用，但它们通常无法实现足够的血糖控制，尤其是在餐后。双相胰岛素类似物是开始和改善2型糖尿病胰岛素治疗的有效工具。天冬胰岛素（BIAsp）分为三种不同的混合物（分别占速效胰岛素的30％，50％和70％），这使胰岛素治疗可以个性化。目的/方法：回顾最近发表的有关BIAsp在2型糖尿病中的药理特性和临床应用的论文。结果/结论：BIAsp似乎比双相人胰岛素具有某些优势，尤其是在餐前或餐后的实际给药以及降低血糖风险方面。对于每天一次的基础胰岛素而言，每天两次的BIAsp似乎在达到葡萄糖目标方面表现更好，即使与更复杂的基础推注方案相比，使用不同的可用混合物进行的基于BIAsp的治疗至少也不逊色。副作用不比其他胰岛素更常见。有时已经报道了更多的严重程度较低的降血糖事件，但仅与基础胰岛素相比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号